About Genable Technologies
Genable Technologies is a company based in Dublin (Ireland) founded in 2001 by Paul Kenna and Jane Farrar was acquired by Spark Therapeutics in March 2016. Genable Technologies has raised $8.11 million across 2 funding rounds from investors including Spark Therapeutics, Fountain Healthcare Partners and Delta Partners. Genable Technologies operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Dublin, Ireland
- Founders Paul Kenna, Jane Farrar
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8.11 M (USD)
in 2 rounds
-
Latest Funding Round
$6.78 M (USD), Series B
Nov 11, 2011
-
Investors
Spark Therapeutics
& 2 more
-
Employee Count
Not available
-
Acquired by
Spark Therapeutics
(Mar 07, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Genable Technologies
Genable Technologies has successfully raised a total of $8.11M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $6.78 million completed in November 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Genable Technologies
Genable Technologies has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Spark Therapeutics, Fountain Healthcare Partners and Delta Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Risk capital is provided to life sciences entrepreneurs.
|
Locked | Locked | Locked | |
|
Early stage venture capital is provided to Irish startups.
|
Locked | Locked | Locked | |
|
Gene therapies for rare diseases including retinal dystrophies are developed.
|
Locked | Locked | Locked |
Investor details for Genable Technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genable Technologies
Investment portfolio details for Genable Technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Genable Technologies
Detailed financials for Genable Technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genable Technologies Comparisons
Peer comparison for Genable Technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Genable Technologies
Genable Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of Genable Technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genable Technologies
Complete news archive for Genable Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genable Technologies
Genable Technologies was founded in 2001 and raised its 1st funding round 3 years after it was founded.
Genable Technologies is headquartered in Dublin, Ireland.
Genable Technologies is a funded company, having raised a total of $8.11M across 2 funding rounds to date.
Provider of gene therapy to treat Retinitis pigmentosa. The first gene medicine - RhoNova formerly known as GT038 - is for the treatment of patients with rhodopsin (RHO)-linked adRP - a debilitating form of inherited blindness resulting from a diverse array of mutations in the RHO gene. It utilizes AAV vectors to obtain expression of RNA interference (RNAi) molecules which suppress the expression of both the faulty and normal gene copies and replaces this with a gene subtly altered to become refractory to suppression but still encoding a normal wild type protein.
Genable Technologies's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Genable Technologies has 3 investors. Key investors include Spark Therapeutics, Fountain Healthcare Partners, and Delta Partners.